HIV Testing: US Recommendations 2014

Authors

  • Justin G. Thomas, DO NSUCOM/Palmetto General Hospital
  • Victor Jaffe, DO NSUCOM/Palmetto General Hospital Family Medicine Residency
  • Judith Shaffer, DO NSUCOM
  • Jose Abreu, MD Palmetto General Hospital

Abstract

Incidence of false positive enzyme-linked immunosorbent assay (ELISA)/enzyme immunoassay (EIA) and indeterminate western blots are expected to rise as the United States Preventive Services Task Force (USPSTF) expands its human immunodeficiency virus HIV testing recommendations to include low-risk populations.  This paper explores current HIV testing recommendations, HIV testing options, causes of false positive or indeterminate results, and how clinicians should proceed when confronted with potential false positive or indeterminate results.  We report two cases in which positive ELISA/EIA and indeterminate western blots required further evaluation and prove to be false positives.  The USPSTF recommends aggressive HIV testing to include screening for all persons 15 to 65 years of age, and younger or older persons who are at increased risk.  They also recommend screening all pregnant women, including those who are untested, who present in labor.  Indeterminate western blot tests should be followed up with nucleic acid testing (NAT) or polymerase chain reaction (PCR) tests, and repeated ELISA/EIA and western blot assays at three and six months.  Fourth generation tests offer an alternative and utilize HIV-1/HIV-2 antibody differentiation immunoassays, in place of western blot assays.

Author Biographies

Justin G. Thomas, DO, NSUCOM/Palmetto General Hospital

Family Medicine Resident

Victor Jaffe, DO, NSUCOM/Palmetto General Hospital Family Medicine Residency

Program Director, Assistant Professor, Department of Family Medicine

Judith Shaffer, DO, NSUCOM

Assistant Professor, NSUCOM, Department of Family Medicine

Jose Abreu, MD, Palmetto General Hospital

Obstetrics and Gynecology

References

Screening for HIV, Topic Page. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm. Accessed May 2014.

Screening for HIV: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 12-05173-EF-4. http://www.uspreventiveservicestaskforce.org/uspstf13/hiv/hivsumm.htm. Accessed May 2014.

Barlett, JG. Medical Management of HIV infection. Port City Press, Baltimore, MD 1998.

Ward JW, Grindon AJ, Feorino PM, Schable C, Parvin M, Allen JR. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA. 1986; 256:357-361.

Centers for Disease Control and Prevention. Current trends update: serologic testing for antibody to human immunodeficiency virus antibodies. Mayo Clin Proc. 1988; 39:833-840.

Erickson CP, McNiff T, Klausner JD. Influenza vaccination and false positive HIV results. N Engl J Med. 2006; 354:1422-3.

Simonsen L, Buffington J, Shapiro CN, Holman RC, Strine TW, Grossman BJ, et al. Multiple false reactions in viral antibody screening assays after influenza vaccination. Am J Epidemiol. 1995; 141:1089-96.

Celum CL, Coombs RW, Jones M, Murphy V, Fisher L, Grant C, et al. Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. Arch Intern Med. 1994; 154:1129-37.

Carlson JR, Yee J, Hinrichs SH, Bryant ML, Gardner MB, Pedersen NC. Comparison of indirect immunofluorescence and Western blot for detection of anti-human immunodeficiency virus antibodies. J Clin Microbiol. 1987; 25:494-497.

Chiodi F, Bredberg-Raden U, Biberfeld G., et al. Radioimmunopercipitation and Western blotting with sera of human immunodeficiency virus infected patients: a comparative study. AIDS Res Hum Retroviruses. 1987; 3:165-176.

Center for Disease Control. Interpretation and Use of the Western Blot Assay for Serodiagnosis of Human Immunodeficiency Virus Type 1 Infections. http://www.cdc.gov. Accessed May 2014.

Centers for Disease Control and Prevention. Interpretive criteria used to report Western blot results for HIV-1 antibody testing: United States. MMWR Morb Mortal Wkly Rep. 1991; 40:692-695.

O’Gorman MRG, Weber D, Landis SE, Schoenbach VI, Manjoo M, Folds JD. Interpretive criteria of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infection. Arch Pathol Lab Med. 1991; 115:26-30.

Centers for Disease Control and Prevention. Interpretation and use of western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep. 1989; 38(suppl 7):1-7.

Dock NL, Kleinman SH, Rayfield MA, Schable CA, Williams AE, Dodd RY. Human immunodeficiency virus infection and indeterminate Western blot patterns. Arch Intern Med. 1991; 151:525-530.

Guan M. Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus. Clin Vaccine Immunol. 2007; 14:649-59.

Vinay S. Mahajan, Christine A. Pace, and Petr Jarolim. Interpretation of HIV Serologic Testing Results. Clinical chemistry. 2010; 56:10 1523-1527.

Centers for Disease Control (CDC). Detection of Acute HIV Infection in Two Evaluations of a New HIV Diagnostic Testing Algorithm — United States, 2011–2013. MMWR. June 21, 2013; 62(24); 489-494.

Downloads

Published

2014-11-07

How to Cite

Thomas, DO, Justin G., et al. “HIV Testing: US Recommendations 2014”. Osteopathic Family Physician, vol. 6, no. 6, Nov. 2014, https://ofpjournal.com/index.php/ofp/article/view/357.

Issue

Section

Review Articles
Received 2014-10-27
Accepted 2014-10-27
Published 2014-11-07

Most read articles by the same author(s)